

Sunday, 29 May 2016

08:00-17:00 Registration

08:45-09:00 **S1: Opening Ceremony**

Chairs: **Stefan Agewall**, Norway; **Basil S. Lewis**, Israel

Hall A

Introductions: Basil S. Lewis, Chairman-Elect, ESC WG on Cardiovascular Pharmacotherapy

Greetings:

Stefan Agewall, Chairman, ESC WG on Cardiovascular Pharmacotherapy

Dan Atar, Vice-President, European Society of Cardiology

Michael Glikson, President, Israel Heart Society

Michael Shechter, Chairman, Israel Heart Society WG on Cardiovascular Pharmacotherapy

09:00-10:30 **S2: New Challenges in Treatment of Hypertension**

Chairs: **Stefan Agewall**, Norway; **Antonio Coca**, Spain; **Yehonatan Sharabi**, Israel

Hall A

Joint Session with ESC Council on Hypertension

09:00 **Best Therapy for Resistant Hypertension: The Pathway Study**

Antonio Coca, Dept. of Hypertension & Vascular Risk Unit Hospital Clinic (IDIBAPS). University of Barcelona, Spain

09:20 **Comparing the Results of Pharmacotherapy vs. Device Intervention in Resistant Hypertension**

Sverre Kjeldsen, Dept. of Cardiology, University of Oslo Ullevaal Hospital, Norway

09:40 **When to Start the Treatment of Arterial Hypertension?**

Juan Tamargo, Dept. of Pharmacology, Universidad Complutense de Madrid, Spain

10:00 **The Changing Pattern of Hypertension Treatment: Arterial Properties and Hemodynamics**

Reuven Zimlichman, Sackler Faculty of Medicine, Tel Aviv University, The E. Wolfson Medical Center, Holon, Israel

10:20 Q & A

10:30-11:00 **Coffee Break, Networking, Exhibition Visit and Posters Viewing**

11:00-12:30 **S3: Hot Topics in Heart Failure**

Chairs: **Gad Keren**, Israel; **Christian Torp-Pedersen**, Denmark

Hall A

11:00 **Debate: Entresto should be First Line Therapy in HFrEF**

Pro: Petar Seferovic, Dept. of Cardiology, Belgrade School of Medicine, Serbia

Con: Giuseppe M.C. Rosano, Cardiovascular Clinical Academic Group, St George's Hospital NHS Trust Medical School, London, UK

11:25 **Debate: SGLT2 Inhibitors for Type 2 Diabetes Mellitus: Do we need HF Specific Trials?**

Pro: Itamar Raz, Diabetes Unit at Hadassah University Hospital, Jerusalem, Israel

Con: Claudio Ceconi, Dept. of Cardiology, University Hospital of Ferrara, Ferrara, Italy

11:50 **Debate: Beta-Blockers and Digoxin can benefit HFrEF Patients with Atrial Fibrillation**

Pro: Dipak Kotecha, Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK

Con: Mitja Lainscak, Dept. of Cardiology, General Hospital Celje, Slovenia

12:15 **Obesity in Heart Failure: Update 2016**

Stefan Anker, Dept. of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany

12:30 Light Lunch

13:00-14:00	Satellite 1: Novartis on Heart Failure Chairs: Felipe Martinez , Argentina; Jean Marc Weinstein , Israel	Hall A
13:00	Role of Neprilysin Inhibitors in CV Disease: What can we learn from PARADIGM? <u>Petar Seferovic</u> , Dept. of Cardiology, Belgrade School of Medicine, Serbia	
13:30	Heart Failure Guidelines 2016: What is New? <u>Stefan Anker</u> , Dept. of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany	
13:45	Panel Discussion: Which Patients and when to use Sacubitril/Valsartan (Entresto)? <u>Offer Amir</u> , <u>Tuvia Ben Gal</u> , <u>Israel Gotsman</u> , <u>Andre Keren</u> , <u>Avi Shotan</u> , Israel	
14:00-15:00	Satellite 2: Boehringer on Diabetes Mellitus Chairs: Avraham Karasik , Israel	Hall A
14:00	Diabetes Therapy: From Glucentric to Complications-Oriented Approach <u>Avraham Karasik</u> , Israel	
14:40	Panel Discussion: Which Patients and when to use Empagliflozin? <u>Rakefet Bacharach</u> , <u>Avraham Karasik</u> , <u>Yoseph Rozenman</u> , Israel	
15:00-16:00	S6: Myocardial and Pericardial Disease: A Case Based Approach to Patient Management Chairs: Yehuda Adler , Israel; Stefan Agewall , Norway; Andre Keren , Israel	Hall A
	<i>Joint Session with ESC Working Group on Myocardial and Pericardial Disease</i>	
15:00	Clinically Suspected Myocarditis with Heart Failure: Treatment? Follow-Up? <u>Shemy Carasso</u> , Baruch Padeh Medical Center, Poriya, Israel	
15:20	Atrial Fibrillation, Treatment with NOAC and Pericarditis: Treatment? Follow-Up? <u>Daniel Monakier</u> , Israel	
15:40	Pericarditis: Treatment? Follow-Up? <u>Dor Lotan</u> , Sheba Medical Center, Tel Hashomer, Israel	
16:00-16:30	Coffee Break, Networking, Exhibition Visit and Posters Viewing	
16:30-18:00	S7: New Directions in Heart Failure Chairs: Stefan Agewall , Norway; Stefan Anker , Germany	Hall A
	<i>Joint Session with Heart Failure Association of the ESC</i>	
16:30	Potassium Lowering Drugs <u>Mitja Lainscak</u> , Dept. of Cardiology, General Hospital Celje, Slovenia	
16:50	Iron Therapy <u>Stefan Anker</u> , Dept. of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany	
17:10	New Therapies for Acute Decompensated Heart Failure <u>Giuseppe Rosano</u> , Cardiovascular Clinical Group, St. George's Hospital NHS Trust Medical School, London, UK	
17:40	Non-Pharmacologic Therapies for Advanced Heart Failure <u>Offer Amir</u> , Dept. of Cardiology, Baruch Padeh Medical Center, Poriya, Israel	
18:00-19:30	<i>Get Together Cocktails</i>	

Monday, 30 May, 2016

08:00	Registration	
08:30-09:30	S8: Gender Differences in Cardiovascular Pharmacotherapy Chairs: Claudio Ceconi , Italy; Mady Moriel , Israel; Zvi Vered , Israel	Hall A
08:30	Gender Differences in Pharmacology <u>Thomas Walther</u> , Dept. of Pharmacology & Therapeutics, University College Cork, Ireland	
08:45	Gender Differences in Clinical Trials <u>Juan Tamargo</u> , Dept. of Pharmacology, Universidad Complutense de Madrid, Madrid, Spain	
09:00	Gender Differences in Cardiovascular Side Effects <u>Giuseppe Rosano</u> , Cardiovascular Clinical Academic Group, St George's Hospital NHS Trust Medical School, London, UK	
09:15	Gender Differences in Treatment Delivery <u>Avital Porter</u> , ICCU and The Women's Cardiac Health Clinic, Rabin Medical Center-Beilinson, and the Sackler Faculty of Medicine, Tel Aviv, Israel	
09:30-10:00	S9: Special Lecture: Breaking News – ESC 2016 Prevention Guidelines Chairs: Stefan Agewall , Norway; Yoseph Shemesh , Israel	Hall A
09:30	What is New in the 2016 European ESC Guidelines on Cardiovascular Disease Prevention? <u>Arno W. Hoes</u> , University Medical Center Utrecht, The Netherlands	
10:00-10:30	Coffee Break, Networking, Exhibition Visit and Posters Viewing	
10:30-11:30	S10: Individualizing Antithrombotic Therapy Chairs: L. Buryachkovskaya , Russia; Nikita Lomakin , Russia; Alexander Niessner , Austria	Hall A
	<i>Russian Scientific Inflammation Society, Central Clinical Hospital of the Presidential Department of Russian Federation</i>	
10:30	Laboratory Monitoring of Antiplatelet Therapy <u>Nikita Lomakin</u> , Russia	
10:50	Genetic Aspects of Antithrombotic Therapy <u>Alexey Meshkov</u> , Russia	
11:10	Role of Local Inflammation in the Development of Instent Restenosis <u>Zufar Gabbasov</u> , Russia	
11:30-13:00	S11: Critical Issues in Antithrombotic Therapy: 2016 Update Chairs: Stefan Agewall , Norway; Joao Morais , Portugal; Amit Segev , Israel	Hall A
	(Supported by an Unrestricted Educational Grant from AstraZeneca)	
	<i>Joint Session with ESC Working Group on Thrombosis</i>	
11:30	DAPT Duration after Stenting in Stable CAD <u>Sven Wassmann</u> , Dept. of Cardiology, Isar Heart Center, Isar Klinikum, Munich, Germany	
11:45	DAPT Duration after Myocardial Infarction <u>Sigrun Halvorsen</u> , Dept. of Cardiology, Oslo University Hospital, Ullevaal, Norway	
12:00	Antithrombotic Therapy in Patients with AF and ACS <u>Dan Atar</u> , Dept. of Cardiology, Oslo University Hospital Ullevaal, Oslo, Norway	
12:15	Should NOACs Totally replace VKA, Aspirin for Stroke Prevention in AF? <u>Joao Morais</u> , Div. of Cardiology, Santo Andre's Hospital, Leiria, Portugal	
12:30	Reversal Strategies for Non-VK Oral Anticoagulants <u>Alexander Niessner</u> , Dept. of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Austria	

12:45 Light Lunch

13:30-14:30 **Satellite 3: Pfizer on NOACs** **Hall A**
Chairs: **Basil Lewis**, Israel; **Yoseph Rozenman**, Israel

13:30 **Modern Stroke Prevention in Atrial Fibrillation: How to Risk Stratify the Patients?
How to Treat the Elderly?**
Dan Atar, Oslo, Norway

13:50 **The Future of Stroke Prevention in NVAF: NOACs for all ?**
Roy Beinart, Tel Hashomer, Israel

14:05 **Which NOAC to whom? Translating the Data into Clinical Decisions**
Michael Glikson, Tel Hashomer, Israel

14:20 **Panel Discussion: Stroke Prevention in NVAF Patients: Challenges in Clinical Practice**

13:30-14:30 **Satellite 4: Amgen on Lipid Lowering** **Hall B**
Chairs: **Yaakov Henkin**, Israel; **Ran Kornowski**, Israel

13:30 **New Era in Lipid Lowering Therapy: PCSK9 Inhibitors: Efficacy, Safety and Early
Promise of CVD Event Reduction**
Evan Stein, USA

14:30-16:00 **S12: Intersociety Opinion: New Drugs and Therapies** **Hall A**
Chairs: **Stefan Agewall**, Norway; **Michael Glikson**, Israel; **Felipe Martinez**, Argentina

Joint Session with International Society of Cardiovascular Pharmacotherapy

14:30 **New Anti-Arrhythmics**
George Dan, University of Medicine "Carol Davila", Bucharest, Romania

14:50 **New Anti-Thrombotics**
Antoni Martínez Rubio, Dept. of Cardiology, University Hospital of Sabadell, Barcelona, Spain

15:10 **New Drugs for Angina and CAD**
Juan Tamarco, Dept. of Pharmacology, Universidad Complutense de Madrid, Madrid, Spain

15:30 **New Drugs for Heart Failure**
Felipe A. Martinez, Cordoba National University, Argentina

15:50 Conclusion

14:30-16:00 **S13: Focus Session: Temporal Trends, Treatments and Outcomes after ACS in Israel:
The Israel National ACSIS Project** **Hall B**
Chairs: **Zaza Iakobishvili**, Israel; **Ran Kornowski**, Israel

Joint Session with the Israel Heart Society Working Group for Acute Cardiac Care

14:30 **ACIS 2000-2013: Overview**
Ilan Goldenberg, Sheba Medical Center and Tel Aviv University, Israel

14:50 **Novel Oral P2Y12 Inhibitors Uptake: Insights from ACSIS 2013 and other Real Life Data**
Roy Beigel, Israel

15:10 **ACIS 2000-2013: Reperfusion Strategies and Outcomes**
Eli Lev, Rabin Medical Center and Tel Aviv University, Israel

15:30 **Panel Discussion:** Moshe Flugelman, Israel; Shmuel Gottlieb, Israel; Sigrun Halvorsen, Norway;
Nikita Lomakin, Russia; Joao Morais, Portugal; Sven Wassmann, Germany

16:00 Conclusion

E-Poster Presentations

- 1. The Level of Uric Acid in Metabolic Syndrome Patient and Way of decreasing it**
Olena Gerasymenko, National University of Pharmacy, Kharkiv, Ukraine
- 2. In Type 2 Diabetics Insulin Therapy is Associated with Micro- But Not Macrovascular Events Independently of Clinical Risk or Coronary Artery Calcium Score – An 8 Year Follow-Up**
David Halon, Dept. of Cardiovascular Medicine, Lady Davis Carmel Medical Centre and Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Israel
- 3. Reckless Administration of QT Interval Prolonging Agents in Elderly Patients with Drug-Induced Torsade De Pointes (TdP)**
Dan Justo, Internal Medicine and Geriatrics D, Sheba Medical Center, Sackler School of Medicine, Tel-Aviv University, Israel
- 4. Hypertension and Comorbidity: Reality Clinical Practice Data: Blood Pressure Control**
Davyd Yakhontov, Novosibirsk Medical University, Russia
- 5. Comparison of Antiplatelet Effects of Different Forms of Acetylsalicylicacid**
Nikita Lomakin, Central Clinical Hospital of President Department of Russian Federation, Moscow, Russian Federation